FDA Drug Safety Podcast: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
On May 16, 2017, based on new data from two large clinical trials, the FDA concluded that the type 2 diabetes medicine canagliflozin (brand names Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - May 25, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
FDA Drug Safety Podcast: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue
On May 22, 2017, FDA announced that to date a review has not identified adverse health effects from gadolinium retained in the brain after the use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI). (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - May 25, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
SCCM Pod-VCCR4 Common Sedatives and Paralytics for Rapid Sequence Intubation
Sean P. Kane, PharmD, BCPS, speaks with Joseph Muench, PharmD, BCPS about airway pharmacology. In the episode, the most common sedatives and paralytics for rapid sequence intubation are discussed, including concepts regarding dosing, adverse effects, onset and duration of effect, and clinical pearls. (Source: SCCM PodCast - iCritical Care)
Source: SCCM PodCast - iCritical Care - May 17, 2017 Category: Intensive Care Authors: The Society of Critical Care Medicine (SCCM) Tags: Medicine Source Type: podcasts
Which Antibiotics Should Be Avoided in Early Pregnancy?
Dr Arefa Cassoobhoy highlights one of the week ' s most important news stories for primary care. (Source: Medscape Pharmacists Podcast)
Source: Medscape Pharmacists Podcast - May 5, 2017 Category: Drugs & Pharmacology Authors: Medscape Source Type: podcasts
The Effect of ER-p53 Combined With Mutant p53
Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics describes the effect and consequences of when ER-p53 tumors attach to mutant p53. This was recorded at the American Associat...
Author: aacr2017
Added: 05/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 2, 2017 Category: Cancer & Oncology Source Type: podcasts
Repurposing Tamoxifen Therapy for Triple Negative Breast Cancer
Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics describes his other study that focuses on the use of tamoxifen therapy for triple negative breast cancer. This was recorded ...
Author: aacr2017
Added: 05/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 2, 2017 Category: Cancer & Oncology Source Type: podcasts
Customizing Therapy Based on p53 Status
Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics discusses how to customize therapy based on the stratification of p53. He further explains with the stratification of p53 st...
Author: aacr2017
Added: 05/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 2, 2017 Category: Cancer & Oncology Source Type: podcasts
Abstract Overview: Novel Effect of Tamoxifen Therapy in Breast Cancer
Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics gives an overview of his abstract, Novel effect of tamoxifen therapy: disruption of ER-p53 interaction leading to altered ge...
Author: aacr2017
Added: 05/02/2017 (Source: Oncology Tube)
Source: Oncology Tube - May 2, 2017 Category: Cancer & Oncology Source Type: podcasts
FDA Drug Safety Podcast: FDA approves label changes for use of general anesthetic and sedation drugs in young children
On April 27, 2017 FDA notified the public that we have approved previously announced label changes regarding the use of general anesthetic and sedation medicines in children younger than 3 years. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - May 1, 2017 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts
Use of Combination Therapy to Extend Duration of Anti-Androgen Therapy Response
David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains the use of combination therapy to extend duration of anti-androgen therapy response. This was...
Author: aacr2017
Added: 04/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 27, 2017 Category: Cancer & Oncology Source Type: podcasts
Initiating Clinical Trials That Can Assess How Patients are Treated
David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses his hopes for new clinical trials that can better assess patient response for treatment. Thi...
Author: aacr2017
Added: 04/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 27, 2017 Category: Cancer & Oncology Source Type: podcasts
Hopes for Targets to Treat ADT Resistant Disease
David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses his hopes for new targets to treat Androgen Deprivation Therapy (ADT) Resistant Disease. Thi...
Author: aacr2017
Added: 04/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 27, 2017 Category: Cancer & Oncology Source Type: podcasts
Do These Variant Cells Pre-Exist in Tumors or is Therapy Causing Transformation
David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains whether or not variant cells pre-exist in tumors or if therapy causes these cells to transfor...
Author: aacr2017
Added: 04/27/2017 (Source: Oncology Tube)
Source: Oncology Tube - April 27, 2017 Category: Cancer & Oncology Source Type: podcasts
